GLP-1 and birth control: what the labels say about the pill

Start a GLP-1 while you’re on the pill, and the two drugs may interact. What the label tells you to do depends on which drug you’re taking.

Tirzepatide’s label (Mounjaro, also sold as Zepbound) tells prescribers to advise backup or non-oral contraception. The semaglutide labels (Ozempic, Wegovy) don’t. Both drug families call for care around planned pregnancy.

The evidence behind these instructions is narrower than the headlines suggest. It comes from small studies that measured hormone levels in blood. None counted pregnancies.

The short version

Tirzepatide: The label advises a non-oral contraceptive or an added barrier method for 4 weeks after starting, and again for 4 weeks after each dose increase.
Semaglutide: The label says the drug is not anticipated to decrease the effect of oral contraceptives. There is no backup instruction.
Pregnancy planning: The Wegovy label advises stopping at least 2 months before a planned pregnancy. Expert-review estimates run shorter.
What is missing: No source here shows that either drug causes contraceptive failure in real-world use.

What the Mounjaro label says

The Mounjaro prescribing information on DailyMed tells prescribers to advise patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method. The window runs 4 weeks after starting Mounjaro and 4 weeks after each dose escalation. The same instruction appears in the label’s section on females and males of reproductive potential.

The reason is delayed gastric emptying. Tirzepatide slows how fast the stomach empties. A pill that reaches the gut later may be absorbed differently. The label describes the effect as largest after the first dose and diminishing over time.

Why the window repeats

The instruction repeats because the dose changes do. Per the 2025 FDA label, dosing starts at 2.5 mg weekly and rises to 5 mg after 4 weeks. Further increases come in 2.5 mg steps after at least 4 weeks on the current dose, up to 15 mg.

Every step-up restarts the 4-week backup window. Someone climbing to the maximum dose faces repeated backup periods. A patient on a stable dose is not in a window.

What the interaction study measured

The Mounjaro label reports one drug-interaction study. A combined oral contraceptive (0.035 mg ethinyl estradiol plus 0.25 mg norgestimate) was given with tirzepatide.

Hormone	Mean Cmax change	Mean AUC change
Ethinyl estradiol	down 59%	down 20%
Norgestimate	down 66%	down 21%
Norelgestromin (active metabolite)	down 55%	down 23%

Time to peak level (tmax) was delayed by 2.5 to 4.5 hours.

Cmax is the peak concentration. AUC is total exposure over time. Peak levels fell by 55% to 66%. Total exposure fell by only 20% to 23%. The pill’s hormones still arrived. They just arrived later and lower at the peak.

The label reports hormone levels, not pregnancies. The FDA’s clinical pharmacology review for tirzepatide is the primary regulatory document behind this finding. It’s a very large file. The label figures above are the numbers verified for this article.

What this does not show

A drop in blood levels is a signal, not an outcome. Three limits matter:

No pregnancy data in the label. The label reports no contraceptive failures or pregnancies in people taking tirzepatide.
The 4-week window is a precaution. It’s a labeling choice tied to dose changes, not a measured duration of risk.
Small study, one pill. The interaction study tested one specific pill formulation. The label doesn’t say how other pills behave.

Real-world failure rates with tirzepatide are not established in the sources used here. The label asks for backup anyway. The pharmacology gives a reason for caution, and backup costs little.

What the semaglutide labels say

Semaglutide labeling (Wegovy and Ozempic) takes the opposite position. The Ozempic prescribing information says semaglutide is not anticipated to decrease the effect of oral contraceptives.

In the label’s interaction study, semaglutide did not change overall exposure of ethinylestradiol and levonorgestrel to a clinically relevant degree. Ethinylestradiol exposure was not affected. Levonorgestrel exposure ran about 20% higher at semaglutide steady state. Unlike the Mounjaro label, this one carries no backup-contraception instruction.

The underlying trials

The dedicated interaction trial behind the label is a published study of once-weekly subcutaneous semaglutide. It concluded that semaglutide does not reduce the bioavailability of the combined pill ethinylestradiol/levonorgestrel. It was a small pharmacokinetic study in healthy volunteers, measuring drug levels rather than pregnancy rates.

A separate pair of trials tested oral semaglutide (Rybelsus) with levonorgestrel/ethinylestradiol. A report in healthy postmenopausal women found AUC ratios of about 1.06 for both hormones. That means no meaningful change. The trial is registered as NCT02845219.

These studies have limits:

They used the oral formulation, not the injectable.
They enrolled postmenopausal women, who are not the population using the pill for contraception.
They were pharmacokinetic only.

So they don’t directly speak to injectable semaglutide in practice, or to pregnancy outcomes. Neither does the evidence for tirzepatide. The two drugs carry different label instructions because their interaction studies found different results. Neither has outcome data in the sources used here.

Wondering how the oral and injectable forms differ otherwise? See our comparison of the Wegovy pill and the injection.

Why gastric emptying is the mechanism to watch

The tirzepatide label points to delayed gastric emptying. That effect reaches beyond the contraceptive question. It also drives other label topics, including gastroparesis warnings and fasting guidance before anesthesia.

Oral drugs depend on the stomach and gut for absorption. A non-oral method doesn’t. That’s the logic behind the label’s advice to switch to a non-oral method or add a barrier method. The labels don’t rank specific methods. Choosing one is a conversation for you and your clinician.

This article doesn’t cover whether vomiting or severe diarrhea affect oral pills in people on GLP-1s. The sources used here don’t address it.

Pregnancy planning and washout

Both drug families call for effective contraception during treatment. Both also call for stopping before a planned pregnancy.

The Wegovy label on DailyMed says patients should be advised of fetal risk when a pregnancy is recognized. Wegovy should be discontinued if used for weight reduction. The label also advises stopping at least 2 months before a planned pregnancy, because of semaglutide’s long half-life. The Mounjaro label likewise says animal studies indicate possible fetal harm.

Different washout estimates

A 2025 narrative review on GLP-1 preconception planning suggests intervals based on about 5 half-lives:

Drug	Suggested washout
Semaglutide	about 35 days or more
Tirzepatide	25 to 35 days or more
Liraglutide	3 days or more

These are expert-review intervals, and they differ from the Wegovy label’s 2-month figure. The review doesn’t discuss contraceptive interactions.

The practical read: for semaglutide, the label is the more conservative number. Treat any washout as something to settle with a clinician before you stop contraception, not after.

Stopping a GLP-1 has other consequences. Our piece on weight regain after stopping Ozempic or Wegovy covers what the studies show, which matters when you plan around a pregnancy.

What to do with this

This isn’t medical advice. These are the questions worth bringing to a prescriber:

Which GLP-1 am I starting? The answer changes the label’s instruction on the pill.
Will I be on a dose escalation schedule? For tirzepatide, each step-up restarts the 4-week backup window.
Should I switch to a non-oral method, or add a barrier method? The tirzepatide label offers both options.
When might I want to conceive? Plan the stop date and the washout before you stop contraception.

Frequently Asked Questions

Does Mounjaro or Zepbound make birth control pills less effective?

The Mounjaro label says tirzepatide may reduce oral contraceptive efficacy through delayed gastric emptying. In the interaction study with an ethinyl estradiol/norgestimate pill, Cmax dropped 55% to 66% and AUC dropped 20% to 23%. The label advises a non-oral method or a barrier method for 4 weeks after starting and after each dose increase. Real-world failure rates aren’t established.

Do Ozempic and Wegovy affect the pill?

The labels say semaglutide is not anticipated to reduce oral contraceptive effect. In the interaction study, ethinylestradiol was unaffected and levonorgestrel was about 20% higher. The semaglutide labels carry no backup-contraception instruction.

Which contraception is not affected by delayed gastric emptying?

The Mounjaro label advises a non-oral method or a barrier method. Non-oral methods don’t rely on stomach absorption. The labels don’t rank specific methods, so ask a clinician which one suits you.

How long should I wait after stopping a GLP-1 before trying to conceive?

The Wegovy label says to discontinue at least 2 months before a planned pregnancy. A narrative review suggests about 5 half-lives: roughly 25 to 35 days or more for tirzepatide and 35 days or more for semaglutide. Make the decision with a clinician.

Can weight loss on a GLP-1 make me more fertile?

Weight loss can restore ovulation in some people with obesity or PCOS. That’s one reason clinicians raise contraception when starting treatment. The evidence is mostly observational or from small trials, and this article cites no pregnancy-rate figures.

This article is for informational purposes only and is not medical advice. Talk to your healthcare provider before starting, stopping, or changing any medication.